Episurf Medical AB (publ)

BATS-CHIXE:EPISBS Stock Report

Market Cap: SEK 97.3m

Episurf Medical Future Growth

Future criteria checks 2/6

Episurf Medical is forecast to grow earnings and revenue by 5.1% and 68.2% per annum respectively. EPS is expected to grow by 41.4% per annum. Return on equity is forecast to be -129.2% in 3 years.

Key information

5.1%

Earnings growth rate

41.4%

EPS growth rate

Medical Equipment earnings growth22.9%
Revenue growth rate68.2%
Future return on equity-129.2%
Analyst coverage

Low

Last updated16 Jul 2024

Recent future growth updates

No updates

Recent updates

No updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:EPISBS - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202660-74-79-731
12/31/202528-78-82-771
12/31/202414-81-81-751
6/30/202412-85-92-84N/A
3/31/202411-92-93-85N/A
12/31/202310-95-94-85N/A
9/30/20234-97-96-85N/A
6/30/20232-94-88-77N/A
3/31/20235-84-85-74N/A
12/31/20227-77-81-69N/A
9/30/202214-72-74-63N/A
6/30/202212-71-72-62N/A
3/31/20229-69-70-61N/A
12/31/20217-69-67-60N/A
9/30/20217-67-63-58N/A
6/30/20217-66-61-56N/A
3/31/20215-63-60-55N/A
12/31/20205-64-59-54N/A
9/30/20205-66-63-58N/A
6/30/20205-69-63-59N/A
3/31/20205-73-66-61N/A
12/31/20195-70-65-59N/A
9/30/20195-66-62-55N/A
6/30/20195-62-69-61N/A
3/31/20194-59-62-54N/A
12/31/20184-58-62-52N/A
9/30/20184-58-64-55N/A
6/30/20183-59-58-49N/A
3/31/20183-55N/A-62N/A
12/31/20173-61N/A-61N/A
9/30/20173-64N/A-59N/A
6/30/20172-65N/A-59N/A
3/31/20172-69N/A-53N/A
12/31/20162-62N/A-56N/A
9/30/20167-57N/A-55N/A
6/30/20168-53N/A-50N/A
3/31/20167-48N/A-44N/A
12/31/20157-44N/A-38N/A
9/30/20152-38N/A-34N/A
6/30/20152-34N/A-34N/A
3/31/20152-32N/A-30N/A
12/31/20142-33N/A-32N/A
9/30/20143-31N/A-31N/A
6/30/20142-28N/A-31N/A
3/31/20142-26N/A-25N/A
12/31/20132-23N/A-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EPISBS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EPISBS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EPISBS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EPISBS's revenue (68.2% per year) is forecast to grow faster than the UK market (3.7% per year).

High Growth Revenue: EPISBS's revenue (68.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EPISBS is forecast to be unprofitable in 3 years.


Discover growth companies